Consequences and implications of the coronavirus disease (COVID‐19) on pregnancy and newborns: A comprehensive systematic review and meta‐analysis

International Journal of Gynecology & Obstetrics, Год журнала: 2021, Номер 156(3), С. 394 - 405

Опубликована: Ноя. 11, 2021

Язык: Английский

---

Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave

Scientific Reports, Год журнала: 2022, Номер 12(1)

Опубликована: Апрель 28, 2022

Cardiovascular adverse conditions are caused by coronavirus disease 2019 (COVID-19) infections and reported as side-effects of the COVID-19 vaccines. Enriching current vaccine safety surveillance systems with additional data sources may improve understanding safety. Using a unique dataset from Israel National Emergency Medical Services (EMS) to 2021, study aims evaluate association between volume cardiac arrest acute coronary syndrome EMS calls in 16-39-year-old population potential factors including infection vaccination rates. An increase over 25% was detected both call types during January-May compared years 2019-2020. Negative Binomial regression models, weekly emergency counts were significantly associated rates 1st 2nd doses administered this age group but not While establishing causal relationships, findings raise concerns regarding vaccine-induced undetected severe cardiovascular underscore already established relationship vaccines myocarditis, frequent cause unexpected young individuals. Surveillance outcomes should incorporate other health identify public trends (e.g., increased calls), promptly investigate underlying causes.

Язык: Английский

---

Stroke Associated with COVID-19 Vaccines

Journal of Stroke and Cerebrovascular Diseases, Год журнала: 2022, Номер 31(6), С. 106440 - 106440

Опубликована: Март 4, 2022

ObjectivesDevelopment of safe and effective vaccines against coronavirus disease 2019 (COVID-19) remains the cornerstone controlling this pandemic. However, there are increasing reports various types stroke including ischemic stroke, hemorrhagic as well cerebral venous sinus thrombosis (CVST) after COVID-19 vaccination. This paper aims to review associated with provide a coherent clinical picture condition.Materials methodsA literature was performed focus on data from recent studies.ResultsMost such patients women under 60 years age who had received ChAdOx1 nCoV-19 vaccine. Most studies reported CVST or without secondary some Vaccine-induced Thrombotic Thrombocytopenia (VITT). The most common symptom seen vaccination headache. course may be more severe than not COVID Management following is challenging differ standard treatment CVST. Low molecular weight heparin commonly used in CVST; however, it worsen outcomes VITT. Furthermore, administration intravenous immunoglobulin high-dose glucocorticoids have been recommended success rates.ConclusionThese contradictory observations source confusion decision-making warrant further study development guidelines. Clinicians should aware presentation, diagnosis, management

Язык: Английский

---

Current view on novel vaccine technologies to combat human infectious diseases

Applied Microbiology and Biotechnology, Год журнала: 2021, Номер 106(1), С. 25 - 56

Опубликована: Дек. 10, 2021

Язык: Английский

---

Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases

Vaccines, Год журнала: 2022, Номер 10(2), С. 232 - 232

Опубликована: Фев. 3, 2022

To date, billions of vaccine doses have been administered to restrain the current COVID-19 pandemic worldwide. Rare side effects, including intravascular blood clots, were reported in general population after vaccination. Among these, cerebral venous sinus thrombosis (CVST) has considered most serious one. shed further light on such an event, we conducted a literature search for case descriptions CVST vaccinated people. Findings analyzed with emphasis demographic characteristics, type vaccine, site thrombosis, clinical and histopathological findings. From 258 potential articles published till September 2021, 41 studies retrieved total 552 patients. Of 492 patients (89.1%) had received AZD1222/Vaxzevria, 45 (8.2%) BNT162b2/CX-024414 Spikevax, 15 (2.7%) JNJ-78436735, 2 (0.3%) Covishield vaccine. occurred 382 women 170 men (mean aged 44 years), median timing from shot was 9 days (range 2-45). Thrombi predominantly seen transverse (84%), sigmoid (66%), and/or superior sagittal (56%) sinuses. Brain injury (chiefly intracranial bleeding) 32% cases. 426 detailed course, 63% discharged good conditions, at times variable neurological sequelae, whereas 37% deceased, largely due brain injury. This narrative review confirmed as rare event (adenoviral vector) vaccination, women/men rate ratio 2.25. Though pathogenesis is still under discussion, currently available findings likely indicate underlying immune vasculitis.

Язык: Английский

---

An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations

Clinical and Applied Thrombosis/Hemostasis, Год журнала: 2022, Номер 28

Опубликована: Янв. 1, 2022

The progress in the development of various vaccine platforms against SARS-CoV-2 have been rather remarkable owing to advancement molecular and biologic sciences. Most current vaccines those focus on targeting viral spike proteins by generating antibodies varying spectrum. These represent a variety including whole virus vaccines, vector nucleic acid representing RNA, DNA, their hybrid forms.The therapeutic efficacy these varies pharmacodynamic individualities. COVID-19 variants are capable inducing different pathologic responses some which may be resistant generated vaccines. clinical use has through emergency authorization until recently. Moreover, safety tested substantial numbers individuals but studies special populations that better reflect global population pending results. specialized include young children, immunocompromised patients, pregnant individuals, other groups. Combination approaches, molecularly modified vaccination conferring longer periods immunity being currently investigated, as well pharmacovigilance studies.The continual transformation its concern along with breakthrough infections. considerations pose new challenges for platforms. For this purpose, booster doses, combination modalities discussed. This review provides an updated account available advanced reference composition mechanisms action.A discussion women also included.

Язык: Английский

---

Cardiovascular Sequelae of the COVID-19 Vaccines

Cureus, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Язык: Английский

---

An unusual presentation of acute deep vein thrombosis after the Moderna COVID-19 vaccine—a case report

Annals of Translational Medicine, Год журнала: 2021, Номер 9(20), С. 1605 - 1605

Опубликована: Сен. 1, 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic of the multisystem disease disease-2019 (COVID-19). Since development COVID-19 vaccines, there been extensive monitoring for potential serious side effects. We report an unusual presentation deep vein thrombosis (DVT) in right upper extremity 27-year-old Caucasian female, 3 days after receipt her second dose Moderna vaccine. Her relevant thrombophilia workup was negative on initial presentation. She treated with rivaroxaban months and symptoms swelling, pain improved. Considering our case did not have any evidence thrombocytopenia, we discuss possible pathophysiology DVT following vaccine contrast to adenoviral vector vaccines (ChAdOx1 nCoV-19 Ad26.COV2.S), including mRNA binding pattern recognition receptors (PRR) endosomes cytosol leading pro inflammatory cascade coagulopathy. highlight importance post vaccination, that should include complete blood count (CBC) platelet count, international normalized ratio (INR), prothrombin time (PTT), D-dimer levels, fibrinogen factor 4 (PF4)/heparin enzyme-linked immunosorbent assays (ELISA) followed by confirmatory PF4 activation assay such as serotonin release assay, P-selectin expression or heparin induced aggregation (HIPA) imaging thrombosis.

Язык: Английский

---

COVID-19 vaccine-induced immune thrombotic thrombocytopenia

Annals of Thoracic Medicine, Год журнала: 2022, Номер 17(1), С. 1 - 13

Опубликована: Янв. 1, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic responsible for the pandemic disease 19 (COVID-19). It has significant impact on human health public safety along with negative social economic consequences. Vaccination against SARS-CoV-2 likely most effective approach to sustainably control global COVID-19 pandemic. in reducing risk of severe disease. Mass-scale vaccination will help us attaining herd immunity lessen health, conditions. The present stimulated development several vaccines based different platforms. Although vaccine safe efficacious, rare cases thrombosis thrombocytopenia following use ChAdOx1 CoV-19 (AstraZeneca, University Oxford, Serum Institute India) or Ad26.COV2.S (Janssen/Johnson & Johnson) have been reported globally. This review focussed definition, epidemiology, pathogenesis, clinical features, diagnosis, management associated thrombosis.

Язык: Английский

---

A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains

Frontiers in Immunology, Год журнала: 2021, Номер 12

Опубликована: Дек. 7, 2021

Facing the imminent need for vaccine candidates with cross-protection against globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants, we present a conserved antigenic peptide RBD9.1 both T-cell and B-cell epitopes. can be recognized by disease 2019 (COVID-19) convalescent serum, particularly those high neutralizing potency. Immunization successfully induce production of receptor-binding domain (RBD)-specific antibodies in Balb/c mice. Importantly, immunized sera exhibit sustained efficacy multiple dominant SARS-CoV-2 variant strains, including B.1.617.2 that carries point mutation (S L452R ) within sequence RBD9.1. Specifically, S Y451 Y454 are identified as key amino acids binding induced RBD-specific to Furthermore, have confirmed 448-456 (NYNYLYRLF)-specific CD8 + response. Both RBD9.1-specific B cells -specific T still activated more than 3 months post last immunization. This study provides potential candidate generate long-term protective over variants, unique functional mechanism activating humoral cellular immunity.

Язык: Английский

---